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ABSTRACT
When compared with Thailand, the seroprevalence of hepatitis A virus (HAV) is extremely high among 
its neighbouring countries. To investigate the seroprevalence of HAV among the Thai people residing in 
the border area between Thailand and Myanmar, 308 residents in Umphang, Maesod district, Tak, were 
recruited. Sera were tested for HAV IgG antibodies by enzyme-linked immunosorbent assay. The overall 
seroprevalence among the Thai people residing in the border area of Thailand was significantly higher than 
that among the general Thai population (71% vs 27% respectively, p<0.05). As asymptomatic or mild HAV 
infection typically occurs in children, the Thai people residing in the border area may receive little benefit 
from universal HAV vaccination. Lower protective antibodies against HAV, along with the exclusion of 
HAV vaccine from the Expanded Programme on Immunization, potentially increase the susceptibility to 
HAV among the general Thai population and may lead to more future outbreaks if HAV is introduced from 
the border areas. The findings suggest that HAV vaccines should be recommended to travellers before their 
journey to the border between Thailand and Myanmar where HAV is endemic.
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INTRODUCTION
The seroprevalence of hepatitis A virus (HAV) in 
most parts of Asia has gradually declined as a result 
of significant improvements in hygiene and living 
standards (1-3). Least-developed countries of the 
region, including Myanmar, Laos, and Cambodia, 
have relatively little impact of these improvements. 
Although the true seroprevalence of HAV in these 
least-developed countries is yet to be determined, 
the seroprevalence is expected to be high. This es-
timation has been derived from the surveillance 
study of HAV antibodies among immigrant workers 
from Myanmar, Laos, and Cambodia in Thailand. 
Immigrant workers from Myanmar had the highest 
rate (100%) of HAV seroprevalence, and this obser-
vation most likely reflects the high prevalence of 
HAV in Myanmar (4).
The seroprevalence of HAV among the Thai people 
residing in the border area adjacent to Myanmar 
is yet to be studied, although, due to geographical 
proximity, it is presumed to be higher than that 
among the general Thai population. The Expanded 
Programme on Immunization (EPI) in Thailand 
has excluded HAV vaccine based on cost-effective 
analysis, indicating that the low incidence of HAV 
infection, along with the cost of the vaccine, tem-
pers its cost-effectiveness (5). Yet, the EPI for the 
general Thai population may not be applicable to 
the Thai people residing in the border area. In this 
report, we investigated the seroprevalence of HAV 
infection among residents in Umphang, Maesod 
district, Tak, Thailand. Tak province is one of the 
border provinces between Thailand and Myanmar 
(Fig. 1), and residents of Tak province were selected 
to represent the Thai people residing in the border 
area.
MATERIALS AND METHODS
The participants included either healthy children 
who had attended the well-child clinic or patients Rianthavorn P et al.
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with acute illness who had attended the outpatient 
clinic or had been hospitalized at the Umphang 
Hospital, Tak, Thailand, during January 2009–June 
2010. 
Sera were collected from the subjects and stored at 
-20  oC until tested for anti-HAV by a commercial 
ELISA (Architect® HAVAb-IgG; Abbott, Wiesbaden, 
Germany) at the Center of Excellence in Clinical 
Virology, Chulalongkorn University, Thailand. The 
seroprevalence of HAV in each age-group was cal-
culated and reported as percentage. The age-related 
seroprevalence of HAV among the people residing 
in the border area was compared with that of Thai 
(6) and Myanmar immigrant workers (4) previously 
reported. The differences of proportions of overall 
HAV seroprevalence in each population were as-
sessed by chi-square test, using the SPSS software 
(version 13) (SPSS, Chicago, IL). Probability values 
of less than 5% were considered to be significant.
Ethical issues
The Institutional Review Board of the Faculty of 
Medicine, Chulalongkorn University, approved the 
study. Informed consent was obtained at the time 
of enrollment. The specimens were used with per-
mission from the Director of the Umphang Hos-
pital, and patient anonymity was maintained. The 
specimens were used solely for academic purposes.
RESULTS
Overall, 308 subjects—149 males and 159 females—
were recruited. The subjects were divided by age, as 
follows: five were aged less than one year, 67 were 
aged 1-6 years, 16 aged 7-12 years, 73 aged 13-20 
years, 45 aged 21-30 years, 33 aged 31-40 years, 23 
aged 41-50 years, 23 aged 51-60 years, and 23 aged 
over 60 years. The overall seroprevalence of HAV 
was 71%. The seroprevalence positively correlated 
with the age of the subjects, except for the infancy 
period (less than 1 year old), which had a high se-
roprevalence of 60%. By the age of 40 years, almost 
every subject had developed HAV IgG antibodies. 
When comparing the seroprevalence of HAV among 
the people residing in the border area with that of 
Thai (6) and Myanmar (4) populations, the age-
related seroprevalence of HAV among the people 
residing in the border area was significantly higher 
than that of the general Thai population (p<0.05) 
but lower than that of Myanmar immigrant work-
ers (p<0.05) (Fig. 2). 
DISCUSSION
HAV remains a major public-health problem wher-
ever hygiene and sanitation are inadequate. Ac-
cordingly, the border area of Thailand is prone to 
sporadic outbreaks of HAV as previously reported 
in a study by Barameechai et al. (7). The seropreva-
lence of HAV among the general Thai population 
has declined, especially in children and young 
adults, during the past two decades while the sero-
prevalence of HAV in the neighbouring countries 
has been persistently high. 
The age-related anti-HAV seroprevalence among 
the people residing in the border area between 
Thailand and Myanmar was in between that ob-
served among the Thai population and Myanmar 
immigrant workers in previous studies. The sero-
prevalence in all three populations increased in 
relation to the age of the subjects and reached its 
peak with the Thai people residing in the border 
area who, on average, were older than Myanmar 
immigrant workers but younger than positive sub-
jects within the general Thai population. As it has 
Fig. 1. Thailand is represented in yellow whereas its 
neighbouring countries, including Myanmar, 
Laos, and Cambodia, are represented in brown 
on the map. Maesod district in Tak province 
is in the border area between Thailand and 
Myanmar and is represented by a red cross    Rianthavorn P et al. HAV in Thai residents near Myanmar border
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been previously shown that HAV IgG antibodies 
can be trans-placentally transferred (8), the spike 
of seroprevalence in infancy merely reflected the 
seroprevalence of HAV infection among women of 
childbearing age which was almost equivalent to 
the overall seroprevalence among this population. 
The results of the present study reflect the hygiene 
and sanitation conditions in the border area of Thai-
land which may have had relatively little improve-
ment when compared with the other parts of the 
country. It was reported that HAV infection in chil-
dren usually exhibits mild non-specific symptoms 
and low case-fatality compared to HAV infection in 
adults (9,10). Figure 2 shows that the seroprevalence 
of HAV was higher among children residing in the 
border area than among the general Thai popula-
tion. Thus, the incidence of severe acute hepatitis 
A might be lower in this area as children infected 
with HAV during childhood usually experience no 
or mild symptoms and acquire protection against 
future symptomatic acute hepatitis A which usual-
ly occurs in adults. Therefore, universal HAV vacci-
nation might be even less cost-effective in the Thai 
population residing in the border area than in the 
general Thai population to whom universal HAV 
vaccination is currently not recommended based 
on the cost-effictive analysis (5). Further studies on 
cost-effectiveness based on the high seroprevalence 
of HAV infection among the Thai population resid-
ing in the border area are necessary for future EPI 
recommendations for Thailand. Lower protective 
antibodies against HAV, along with the exclusion 
of HAV vaccine from the EPI, potentially increase 
the susceptibility of the general Thai population to 
HAV and may lead to more future outbreaks if HAV 
is introduced from the border areas. HAV vaccines 
should be recommended to travellers before their 
journey to the border between Thailand and My-
anmar where HAV remains endemic.
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